CRISPR Limits Impact of Certain Parasitic Diseases

May 14, 2019

For the first time, researchers at the George Washington University (GW), with colleagues at institutes in Thailand, Australia, the United Kingdom, and the Netherlands, have successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and liver fluke infection.

CRISPR test tube

Their findings were reported in two papers published in the journal eLife. CRISPR/Cas9 is a technology that allows researchers to precisely target and deactivate the genetic information needed to produce a particular protein.

“The genes we ‘knocked out’ using CRISPR/Cas9 resulted in markedly diminished symptoms of infection in our animal models,” said Paul Brindley, PhD, professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences and lead author of the paper. “Our research also showed that this revolutionary new biomedical procedure — CRISPR/Cas9 — can be adapted to study helminth parasites, which are a major public health problem in tropical climates.”

Latest News

September 23, 2021
Celebrating the George Washington University bicentennial reflecting on the School of Medicine and Health Sciences’s (SMHS) 197 years at the university.
March 2, 2021
The George Washington University is participating in another COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a Phase II study for the Sanofi COVID-19 adjuvanted recombinant protein-based COVID-19 vaccine candidate.
February 25, 2021
The George Washington University (GW) Office of the Vice President for Research and the GW School of Medicine and Health Sciences gave COVID-19 research a shot in the arm through the FY21 COVID-19 Research Fund competition.